Earnings season is upon us again, and most public cannabis companies will release results for the 4th quarter of 2022 in the next few weeks. Only two of the companies in the graph have reported to date. Green Thumb (OTC: GTBIF) beat consensus revenue estimates by 1% and EBITDA estimates by 1.2%, while MariMed (OTC: MRMD) beat revenue estimates by 2% but missed EBITDA by 33.8%.
In digesting the releases, investors will pay particular attention to EBITDA and cash levels—achieving positive cash flow and maintaining liquidity trump growth in this environment.
We will also be focusing on estimate revisions. We have been tracking consensus analyst estimates for 2023 since the beginning of 2022. The orange line on the graph shows the percentage reduction in 2023 consensus EBITDA estimates from 12/31/21 to 3/3/23. The average EBITDA estimate reduction is 51.6%.
The blue line on the graph shows the percentage decrease in enterprise value over the same period. Schwazze (SHWZ: OTC) is the only company on the chart with increased enterprise value over the period. Interestingly, SHWZ also has the …